Novartis is making further workforce reductions at its U.S. headquarters in New Jersey, planning to remove 114 positions as ...

Envision Pharma Group has hired clinical research veteran Nick Jones as president of its Envision Medical Communications (EMC ...

Amneal and BioCorRx have earned the ire of the FDA’s Office of Prescription Drug Promotion (OPDP), with both being hit by ...

Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear look at which ...

Takeda ended its neurogenerative disease partnership with Denali Therapeutics. Merck & Co. and Zhifei have scrapped a minimum ...

Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the ...

AbbVie is spearheading a new battle in pharma's long-running fight to reform the federal government’s 340B drug discount ...

In connection with the deal, Assertio has divested the rest of its assets to New Jersey generics and branded drugmaker ...

In December, Vanda Pharmaceuticals gained FDA approval for its motion sickness drug Nereus. But a much larger patient population may be in store for the oral therapy as the Washington, D.C.-based ...

Robert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services ...

Pfizer is making more changes to its layout in California by stepping away from a South San Francisco office site that used ...

Japan’s Shionogi is joining the spate of drugmakers to announce manufacturing commitments in the U.S. since last year, albeit ...